Advanced in Multiple Myeloma

Dr. Zdenka Segota

Hematology
Baptist Health Lynn Cancer Institute | Delray
6282 Linton Blvd, 
Delray Beach, FL 
Accepting New Patients
Offers Telehealth
Advanced in Multiple Myeloma
Baptist Health Lynn Cancer Institute | Delray
6282 Linton Blvd, 
Delray Beach, FL 

Overview

Zdenka Segota is a Hematologist in Delray Beach, Florida. Dr. Segota is rated as an Advanced provider by MediFind in the treatment of Multiple Myeloma. Her top areas of expertise are Inflammatory Breast Cancer, Breast Cancer, Paget Disease of the Breast, and Angiosarcoma. Dr. Segota is currently accepting new patients.

Her clinical research consists of co-authoring 2 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Hematology

Licenses

Internal Medicine in ME

Hospital Affiliations

Boca Raton Regional Hospital
Delray Medical Center
Holy Cross Hospital

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Florida Blue
  • EPO
  • PPO
Health Options
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medical Mutual
  • HMO
  • PPO
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

Baptist Health Lynn Cancer Institute | Delray
6282 Linton Blvd, Delray Beach, FL 33484
Other Locations
Baptist Health Lynn Cancer Institute | Boca Raton
701 NW 13th St, Boca Raton, FL 33486

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

An Open-Label, Multicenter Follow-up Study to Collect Long-term Data on Participants From Multiple Avelumab (MSB0010718C) Clinical Studies
An Open-Label, Multicenter Follow-up Study to Collect Long-term Data on Participants From Multiple Avelumab (MSB0010718C) Clinical Studies
Enrollment Status: Active_not_recruiting
Publish Date: December 04, 2025
Intervention Type: Drug
Study Drug: Avelumab
Study Phase: Phase 3
MONARCH 2: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Fulvestrant With or Without Abemaciclib, a CDK4/6 Inhibitor, for Women With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer
MONARCH 2: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Fulvestrant With or Without Abemaciclib, a CDK4/6 Inhibitor, for Women With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 21, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Fulvestrant
Study Phase: Phase 3
A Phase III Multi-center, Randomized, Open-label Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negative Early Breast Cancer (New Adjuvant TriAl With Ribociclib [LEE011]: NATALEE)
A Phase III Multi-center, Randomized, Open-label Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negative Early Breast Cancer (New Adjuvant TriAl With Ribociclib [LEE011]: NATALEE)
Enrollment Status: Active_not_recruiting
Publish Date: October 21, 2025
Intervention Type: Drug, Other
Study Drug: Ribociclib
Study Phase: Phase 3
An Open Label, Phase Ia/Ib Trial of the DNA-PK Inhibitor MSC2490484A in Combination With Radiotherapy in Patients With Advanced Solid Tumors
An Open Label, Phase Ia/Ib Trial of the DNA-PK Inhibitor MSC2490484A in Combination With Radiotherapy in Patients With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: October 15, 2024
Intervention Type: Drug, Radiation
Study Phase: Phase 1
An Open Label, Multi-center Protocol for U.S. Patients Enrolled in a Study of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negative, High Risk Early Breast Cancer
An Open Label, Multi-center Protocol for U.S. Patients Enrolled in a Study of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negative, High Risk Early Breast Cancer
Enrollment Status: Completed
Publish Date: October 11, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2 Open Label, Multi-Center, Multinational, Randomized, Parallel Design Study Investigating The Efficacy and Safety Of GTx-024 On Metastatic or Locally Advanced ER+/AR+ Breast Cancer (BC) in Postmenopausal Women
A Phase 2 Open Label, Multi-Center, Multinational, Randomized, Parallel Design Study Investigating The Efficacy and Safety Of GTx-024 On Metastatic or Locally Advanced ER+/AR+ Breast Cancer (BC) in Postmenopausal Women
Enrollment Status: Completed
Publish Date: December 09, 2020
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2 Open Label, Multi-Center, Multinational Study Investigating The Efficacy and Safety Of GTx-024 On Advanced, Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC)
A Phase 2 Open Label, Multi-Center, Multinational Study Investigating The Efficacy and Safety Of GTx-024 On Advanced, Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC)
Enrollment Status: Terminated
Publish Date: November 18, 2020
Intervention Type: Drug
Study Phase: Phase 2
CANscriptTM Clinical Outcomes in a Real-World Setting (ANCERS)-2: A Prospective, Multicenter, Observational Study Examining the Clinical Utility of CANscriptTM in Routine Clinical Practice
CANscriptTM Clinical Outcomes in a Real-World Setting (ANCERS)-2: A Prospective, Multicenter, Observational Study Examining the Clinical Utility of CANscriptTM in Routine Clinical Practice
Enrollment Status: Suspended
Publish Date: April 08, 2019
Intervention Type: Diagnostic test
View 7 Less Clinical Trials

2 Total Publications

Unusual Brain Lesions Diagnosed From a Cerebrospinal Fluid Wet Preparation in a Patient With AIDS.
Unusual Brain Lesions Diagnosed From a Cerebrospinal Fluid Wet Preparation in a Patient With AIDS.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: May 24, 2020
Similar Doctors
Elite in Multiple Myeloma
Dr. Guenther Koehne
Hematology | Oncology
Elite in Multiple Myeloma
Dr. Guenther Koehne
Hematology | Oncology

Baptist Health Miami Cancer Institute

8900 N Kendall Dr, 
Miami, FL 
 (49.2 miles away)
786-345-7208
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Guenther Koehne is a Hematologist and an Oncologist in Miami, Florida. Dr. Koehne is rated as a Distinguished provider by MediFind in the treatment of Multiple Myeloma. His top areas of expertise are Multiple Myeloma, Wilms Tumor, Smoldering Multiple Myeloma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Koehne is currently accepting new patients.

Distinguished in Multiple Myeloma
Dr. James Hoffman
Hematology
Distinguished in Multiple Myeloma
Dr. James Hoffman
Hematology

Sylvester Comprehensive Cancer Center-Deerfield Beach

1192 E Newport Center Dr, 
Deerfield Beach, FL 
 (4.4 miles away)
954-571-0111
Languages Spoken:
English
See accepted insurances
Offers Telehealth

James Hoffman is a Hematologist in Deerfield Beach, Florida. Dr. Hoffman is rated as a Distinguished provider by MediFind in the treatment of Multiple Myeloma. His top areas of expertise are Smoldering Multiple Myeloma, Multiple Myeloma, Hereditary Cerebral Amyloid Angiopathy, and Primary Localized Cutaneous Amyloidosis.

Distinguished in Multiple Myeloma
Dr. Warren Brenner
Hematology | Oncology
Distinguished in Multiple Myeloma
Dr. Warren Brenner
Hematology | Oncology

Baptist Health Lynn Cancer Institute | Boca Raton

701 NW 13th St, 
Boca Raton, FL 
 (0.1 miles away)
561-639-8831
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Warren Brenner is a Hematologist and an Oncologist in Boca Raton, Florida. Dr. Brenner is rated as a Distinguished provider by MediFind in the treatment of Multiple Myeloma. His top areas of expertise are Pancreatic Cancer, Familial Pancreatic Cancer, Anal Cancer, and Familial Colorectal Cancer. Dr. Brenner is currently accepting new patients.

Frequently Asked Questions about Dr. Zdenka Segota

How do I make an appointment with Dr. Zdenka Segota?

You can book an appointment with Dr. Zdenka Segota by calling their office at 561-567-7886. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Zdenka Segota a top-rated expert for Inflammatory Breast Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Zdenka Segota is classified as an Distinguished expert for Inflammatory Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Zdenka Segota specialize in?

While Dr. Zdenka Segota is a Hematology, they have specific expertise in Inflammatory Breast Cancer, Breast Cancer, and Paget Disease of the Breast. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Zdenka Segota participate in research or clinical trials?

Yes. Dr. Zdenka Segota has published 2 articles and abstracts on conditions like Inflammatory Breast Cancer. You can view a list of Dr. Zdenka Segota's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Zdenka Segota accept my insurance?

Dr. Zdenka Segota accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 561-567-7886 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Segota's expertise for a condition
ConditionClose
    View All 35 Advanced Conditions
    View All 133 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile